磁共振氫波譜技術在腫瘤臨床診療研究中的進展_West China Medical Journal

Authors：

 張晗媚 ¹ , 甘奇 ² , 宋彬 ¹ ,  鄔穎華 ³

1. ;
2. ;
3. ;

Corresponding?author：

鄔穎華, Email: wuyinghua_1111@163.com

Keywords：

功能磁共振技術; 波譜成像; 磁共振氫波譜技術; 腫瘤診斷; 腫瘤療效評價

DOI：

10.7507/1002-0179.20140722

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

磁共振波譜（MRS）成像技術作為一種無創的功能影像學方法，廣泛應用于臨床多領域的研究，包括當今研究熱點臨床腫瘤診斷和療效評價。現以MRS技術中最常用的氫質子波譜（1H-MRS）為對象，由成像原理、檢測意義入手，就1H-MRS技術在腫瘤診療研究中的新進展作一綜述，以客觀評估該技術在臨床腫瘤診斷和療效評價中的應用。

Citation： 張晗媚, 甘奇, 宋彬, 鄔穎華. 磁共振氫波譜技術在腫瘤臨床診療研究中的進展. West China Medical Journal, 2014, 29(12): 2387-2390. doi: 10.7507/1002-0179.20140722 Copy

1.	曹開明, 郝楠馨, 常時新. 1H-MRS在腎臟腫瘤的應用[J]. 同濟大學學報·醫學版, 2006, 27(增刊1):69-71.
2.	Zira AN, Theocharis SE, Mitropoulos D, et al. (1)H NMR metabonomic analysis in renal cell carcinoma:a possible diagnostic tool[J]. J Proteome Res, 2010, 9(8):4038-4044.
3.	Schwerk A, Alves FD, Pouwels PJ, et al. Metabolic alterations associated with schizophrenia:a critical evaluation of proton magnetic resonance spectroscopy studies[J]. J Neurochem, 2014, 128(1):1-87.
4.	Murphy G, Haider M, Ghai S, et al. The expanding role of MRI in prostate cancer[J]. Am J Roentgenol, 2013, 201(6):1229-1238.
5.	Geethanath S, Baek HM, Ganji SK, et al. Compressive sensing could accelerate 1H Mr metabolic imaging in the clinic[J]. Radiology, 2012, 262(3):985-994.
6.	Falk MJ, Li D, Gai X, et al. AGC1 deficiency causes infantile epilepsy, abnormal myelination, and reduced N-Acetylaspartate[J/OL]. JIMD Rep. (2014-02-11)[2014-07-01]. http://link.springer.com/chapter/10.1007%2F8904_2013_287.
7.	Kim DY, Kim KB, Kim OD, et al. Localized in vivo proton spectroscopy of renal cell carcinoma in human kidney[J]. J Korean Med Sci, 1998, 13(1):49-53.
8.	Kraguljac NV, Reid M, White D, et al. Neurometabolites in schizophrenia and bipolar disorder:a systematic review and meta-analysis[J]. Psychiatry Res, 2012, 203(2/3):111-125.
9.	包尚聯, 孫啟玉, 謝宜學. 磁共振譜成像及其在腫瘤診療中的應用[J]. 中國醫療器械信息, 2005, 11(2):6-8.
10.	Sarkar BK, Chakraborty C, Sharma AR, et al. Novel biomarker for prostate cancer diagnosis by MRS[J]. Front Biosci (Landmark Ed), 2014, 19(19):1186-1201.
11.	白玉貞, 韓曉東, 牛廣明. 1H-MRS診斷腦膠質瘤的臨床應用進展[J]. 內蒙古醫學院學報, 2009, 31(1):70-75.
12.	Chawalparit O, Sangruchi T, Witthiwej T, et al. Diagnostic performance of advanced MRI in differentiating high-grade from low-grade gliomas in a setting of routine service[J]. Med Assoc Thai, 2013, 96(10):1365-1373.
13.	潘初, 朱文珍, 黃博, 等. 腦膠質瘤病的MRI及MRS研究[J]. 放射學實踐, 2004, 19(9):631-634.
14.	Bendszus M, Warmuth-Metz M, Klein R, et al. Mr spectroscopy in gliomatosis cerebri[J]. Am J Neuroradiol, 2000, 21(2):375-380.
15.	De Carvalho Neto A, Gasparetto EL, Bruck I. Subependymal giant cell astrocytoma with high choline/creatine ratio on proton Mr spectroscopy[J]. Arq Neuropsiquiatr, 2006, 64(3B):877-880.
16.	Majós C, Alonso J, Aguilera C, et al. Adult primitive neuroectodermal tumor:proton Mr spectroscopic findings with possible application for differential diagnosis[J]. Radiology, 2002, 225(2):556-565.
17.	陳鵬, 趙衛東, 張紅宇, 等. 肝細胞癌患者1.5T氫質子磁共振波譜分析[J]. 中國癌癥雜志, 2010, 20(1):55-58.
18.	Kuo YT, Li CW, Chen CY, et al. In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T Mr scanner[J]. J Magn Reson Imaging, 2004, 19(5):598-604.
19.	顏榮華, 肖恩華, 梁斌. 1.5 T磁共振兔VX2肝癌活體二維多體素1H-MRS應用初探[J]. 臨床放射學雜志, 2005, 24(12):1097-1102.
20.	Lassel EA, Rao R, Schwenke C, et al. Diffusion-weighted imaging of focal renal lesions:a meta-analysis[J]. Eur Radiol, 2014, 24(1):241-249.
21.	Corcoran AT, Russo P, Lowrance WT, et al. A review of contemporary data on surgically resected renal Masses-Benign or malignant?[J]. Urology, 2013, 81(4):707-713.
22.	Taouli B, Thakur RK, Mannelli L, et al. Renal lesions:characterization with diffusion-weighted imaging versus contrast-enhanced Mr imaging[J]. Radiology, 2009, 251(2):398-407.
23.	Chung MS, Choi HJ, Kim MH, et al. Comparison of T2-Weighted MRI with and without fat suppression for differentiating renal angiomyolipomas without visible fat from other renal tumors[J]. Am J Roentgenol, 2014, 202(4):765-771.
24.	蔣濤, 韓希年, 肖湘生. 磁共振質子波譜分析在腎臟腫瘤中的應用[J]. 實用放射學雜志, 2006, 22(10):1273-1276.
25.	Katz-Brull R, Rofsky NM, Morrin MM, et al. Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy[J]. Am J Physiol Renal Physiol, 2005, 288(4):F637-F641.
26.	Righi V, Mucci A, Schenetti L, et al. Ex vivo HR-MAS magnetic resonance spectroscopy of normal and malignant human renal tissues[J]. Anticancer Res, 2007, 27(5A):3195-3204.
27.	Gao H, Dong B, Jia J, et al. Application of ex vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases[J]. J Cancer Res Clin Oncol, 2012, 138(5):753-761.
28.	Reeves GK, Beral V, Bull D, et al. Estimating relative survival among people registered with cancer in England and Wales[J]. Br J Cancer, 1999, 79(1):18-22.
29.	孫穎浩. 我國前列腺癌的現狀研究[J]. 中華泌尿外科雜志, 2004, 25(2):77-80.
30.	黃松濤, 卜麗紅, 王景林, 等. 磁共振波譜對前列腺癌的診斷價值[J]. 哈爾濱醫科大學學報, 2010, 44(2):171-173, 176.
31.	Sarici H, Telli O, Yigitbasi O, et al. Predictors of gleason score upgrading in patients with prostate biopsy gleason score ≤ 6[J]. Can Urol Assoc J, 2014, 8(5/6):E342-E346.
32.	王霄英, 周良平, 李飛宇, 等. 前列腺癌的MR波譜特征與Gleason評分的關系[J]. 中華放射學雜志, 2006, 40(11):1181-1184.
33.	Isobe T, Matsumura A, Anno I, et al. Changes in 1H-MRS in glioma patients before and after irradiation:the significance of quantitative analysis of choline-containing compounds[J]. No Shinkei Geka, 2003, 31(2):167-172.
34.	Weybright P, Sundgren PC, Maly P, et al. Differentiation between brain tumor recurrence and radiation injury using Mr spectroscopy[J]. AJR Am J Roentgenol, 2005, 185(6):1471-1476.
35.	Wu B, Peng WJ, Wang PJ, et al. In vivo 1H magnetic resonance spectroscopy in evaluation of hepatocellular carcinoma and its early response to transcatheter arterial chemoembolization[J]. Chin Med Sci J, 2006, 21(4):258-264.
36.	羅銀燈, 鐘維佳, 趙建農, 等. 磁共振氫質波譜成像評估高強度聚焦超聲治療原發性肝癌療效的可行性及其價值[J]. 中華肝臟病雜志, 2011, 19(2):102-105.
37.	卞讀軍, 肖恩華. 質子磁共振波譜成像技術及其在肝癌的臨床應用[J]. 中華臨床醫師雜志·電子版, 2011, 5(23):7012-7015.

1. 曹開明, 郝楠馨, 常時新. 1H-MRS在腎臟腫瘤的應用[J]. 同濟大學學報·醫學版, 2006, 27(增刊1):69-71.
2. Zira AN, Theocharis SE, Mitropoulos D, et al. (1)H NMR metabonomic analysis in renal cell carcinoma:a possible diagnostic tool[J]. J Proteome Res, 2010, 9(8):4038-4044.
3. Schwerk A, Alves FD, Pouwels PJ, et al. Metabolic alterations associated with schizophrenia:a critical evaluation of proton magnetic resonance spectroscopy studies[J]. J Neurochem, 2014, 128(1):1-87.
4. Murphy G, Haider M, Ghai S, et al. The expanding role of MRI in prostate cancer[J]. Am J Roentgenol, 2013, 201(6):1229-1238.
5. Geethanath S, Baek HM, Ganji SK, et al. Compressive sensing could accelerate 1H Mr metabolic imaging in the clinic[J]. Radiology, 2012, 262(3):985-994.
6. Falk MJ, Li D, Gai X, et al. AGC1 deficiency causes infantile epilepsy, abnormal myelination, and reduced N-Acetylaspartate[J/OL]. JIMD Rep. (2014-02-11)[2014-07-01]. http://link.springer.com/chapter/10.1007%2F8904_2013_287.
7. Kim DY, Kim KB, Kim OD, et al. Localized in vivo proton spectroscopy of renal cell carcinoma in human kidney[J]. J Korean Med Sci, 1998, 13(1):49-53.
8. Kraguljac NV, Reid M, White D, et al. Neurometabolites in schizophrenia and bipolar disorder:a systematic review and meta-analysis[J]. Psychiatry Res, 2012, 203(2/3):111-125.
9. 包尚聯, 孫啟玉, 謝宜學. 磁共振譜成像及其在腫瘤診療中的應用[J]. 中國醫療器械信息, 2005, 11(2):6-8.
10. Sarkar BK, Chakraborty C, Sharma AR, et al. Novel biomarker for prostate cancer diagnosis by MRS[J]. Front Biosci (Landmark Ed), 2014, 19(19):1186-1201.
11. 白玉貞, 韓曉東, 牛廣明. 1H-MRS診斷腦膠質瘤的臨床應用進展[J]. 內蒙古醫學院學報, 2009, 31(1):70-75.
12. Chawalparit O, Sangruchi T, Witthiwej T, et al. Diagnostic performance of advanced MRI in differentiating high-grade from low-grade gliomas in a setting of routine service[J]. Med Assoc Thai, 2013, 96(10):1365-1373.
13. 潘初, 朱文珍, 黃博, 等. 腦膠質瘤病的MRI及MRS研究[J]. 放射學實踐, 2004, 19(9):631-634.
14. Bendszus M, Warmuth-Metz M, Klein R, et al. Mr spectroscopy in gliomatosis cerebri[J]. Am J Neuroradiol, 2000, 21(2):375-380.
15. De Carvalho Neto A, Gasparetto EL, Bruck I. Subependymal giant cell astrocytoma with high choline/creatine ratio on proton Mr spectroscopy[J]. Arq Neuropsiquiatr, 2006, 64(3B):877-880.
16. Majós C, Alonso J, Aguilera C, et al. Adult primitive neuroectodermal tumor:proton Mr spectroscopic findings with possible application for differential diagnosis[J]. Radiology, 2002, 225(2):556-565.
17. 陳鵬, 趙衛東, 張紅宇, 等. 肝細胞癌患者1.5T氫質子磁共振波譜分析[J]. 中國癌癥雜志, 2010, 20(1):55-58.
18. Kuo YT, Li CW, Chen CY, et al. In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T Mr scanner[J]. J Magn Reson Imaging, 2004, 19(5):598-604.
19. 顏榮華, 肖恩華, 梁斌. 1.5 T磁共振兔VX2肝癌活體二維多體素1H-MRS應用初探[J]. 臨床放射學雜志, 2005, 24(12):1097-1102.
20. Lassel EA, Rao R, Schwenke C, et al. Diffusion-weighted imaging of focal renal lesions:a meta-analysis[J]. Eur Radiol, 2014, 24(1):241-249.
21. Corcoran AT, Russo P, Lowrance WT, et al. A review of contemporary data on surgically resected renal Masses-Benign or malignant?[J]. Urology, 2013, 81(4):707-713.
22. Taouli B, Thakur RK, Mannelli L, et al. Renal lesions:characterization with diffusion-weighted imaging versus contrast-enhanced Mr imaging[J]. Radiology, 2009, 251(2):398-407.
23. Chung MS, Choi HJ, Kim MH, et al. Comparison of T2-Weighted MRI with and without fat suppression for differentiating renal angiomyolipomas without visible fat from other renal tumors[J]. Am J Roentgenol, 2014, 202(4):765-771.
24. 蔣濤, 韓希年, 肖湘生. 磁共振質子波譜分析在腎臟腫瘤中的應用[J]. 實用放射學雜志, 2006, 22(10):1273-1276.
25. Katz-Brull R, Rofsky NM, Morrin MM, et al. Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy[J]. Am J Physiol Renal Physiol, 2005, 288(4):F637-F641.
26. Righi V, Mucci A, Schenetti L, et al. Ex vivo HR-MAS magnetic resonance spectroscopy of normal and malignant human renal tissues[J]. Anticancer Res, 2007, 27(5A):3195-3204.
27. Gao H, Dong B, Jia J, et al. Application of ex vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases[J]. J Cancer Res Clin Oncol, 2012, 138(5):753-761.
28. Reeves GK, Beral V, Bull D, et al. Estimating relative survival among people registered with cancer in England and Wales[J]. Br J Cancer, 1999, 79(1):18-22.
29. 孫穎浩. 我國前列腺癌的現狀研究[J]. 中華泌尿外科雜志, 2004, 25(2):77-80.
30. 黃松濤, 卜麗紅, 王景林, 等. 磁共振波譜對前列腺癌的診斷價值[J]. 哈爾濱醫科大學學報, 2010, 44(2):171-173, 176.
31. Sarici H, Telli O, Yigitbasi O, et al. Predictors of gleason score upgrading in patients with prostate biopsy gleason score ≤ 6[J]. Can Urol Assoc J, 2014, 8(5/6):E342-E346.
32. 王霄英, 周良平, 李飛宇, 等. 前列腺癌的MR波譜特征與Gleason評分的關系[J]. 中華放射學雜志, 2006, 40(11):1181-1184.
33. Isobe T, Matsumura A, Anno I, et al. Changes in 1H-MRS in glioma patients before and after irradiation:the significance of quantitative analysis of choline-containing compounds[J]. No Shinkei Geka, 2003, 31(2):167-172.
34. Weybright P, Sundgren PC, Maly P, et al. Differentiation between brain tumor recurrence and radiation injury using Mr spectroscopy[J]. AJR Am J Roentgenol, 2005, 185(6):1471-1476.
35. Wu B, Peng WJ, Wang PJ, et al. In vivo 1H magnetic resonance spectroscopy in evaluation of hepatocellular carcinoma and its early response to transcatheter arterial chemoembolization[J]. Chin Med Sci J, 2006, 21(4):258-264.
36. 羅銀燈, 鐘維佳, 趙建農, 等. 磁共振氫質波譜成像評估高強度聚焦超聲治療原發性肝癌療效的可行性及其價值[J]. 中華肝臟病雜志, 2011, 19(2):102-105.
37. 卞讀軍, 肖恩華. 質子磁共振波譜成像技術及其在肝癌的臨床應用[J]. 中華臨床醫師雜志·電子版, 2011, 5(23):7012-7015.

Previous Article
CYP2C19基因多態性與個體化治療的研究進展
Next Article
重癥急性胰腺炎胰腺感染的危險因素研究進展

West China Medical Journal

磁共振氫波譜技術在腫瘤臨床診療研究中的進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content